Overview

CVRx develops BAROSTIM NEO, a neuromodulation therapy for heart failure. The device delivers electrical stimuli to baroreceptors in the cardiovascular system to modulate nerve activity and support blood pressure regulation, aiming to improve heart function in patients who struggle with fatigue, shortness of breath, and fluid retention. The system works through an implanted or wearable neuromodulation device that interacts with the body's nerve signals to influence cardiovascular control. CVRx differentiates itself by offering a focused solution for heart failure that combines the device with provider-focused support programs to facilitate patient access and reimbursement, working with hospitals and clinics to implement therapy. The company's goal is to improve patient outcomes for heart failure and expand the adoption of BAROSTIM THERAPY by helping healthcare providers treat more patients effectively.